178 related articles for article (PubMed ID: 31778549)
1. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.
Stein BL; Martin K
Blood; 2019 Nov; 134(22):1902-1911. PubMed ID: 31778549
[TBL] [Abstract][Full Text] [Related]
2. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.
Stein BL; Martin K
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):397-406. PubMed ID: 31808903
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.
Martin K
Curr Hematol Malig Rep; 2017 Oct; 12(5):389-396. PubMed ID: 28948496
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.
De Stefano V; Teofili L; Leone G; Michiels JJ
Semin Thromb Hemost; 1997; 23(5):411-8. PubMed ID: 9387199
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH).
Appelmann I; Kreher S; Parmentier S; Wolf HH; Bisping G; Kirschner M; Bergmann F; Schilling K; Brümmendorf TH; Petrides PE; Tiede A; Matzdorff A; Griesshammer M; Riess H; Koschmieder S
Ann Hematol; 2016 Apr; 95(5):707-18. PubMed ID: 26916570
[TBL] [Abstract][Full Text] [Related]
6. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.).
Kreher S; Ochsenreither S; Trappe RU; Pabinger I; Bergmann F; Petrides PE; Koschmieder S; Matzdorff A; Tiede A; Griesshammer M; Riess H; ; ;
Ann Hematol; 2014 Dec; 93(12):1953-63. PubMed ID: 25307456
[TBL] [Abstract][Full Text] [Related]
7. Acquired von Willebrand syndrome: an important bleeding complication to be considered in patients with lymphoproliferative and myeloproliferative disorders.
Federici AB; Rand JH; Mannucci PM
Hematol J; 2001; 2(6):358-62. PubMed ID: 11920274
[No Abstract] [Full Text] [Related]
8. [Thrombosis and platelet dysfunction in myeloproliferative neoplasms].
Mornet C; Galinat H; Mingant F; Ianotto JC; Lippert E
Rev Med Interne; 2020 May; 41(5):319-324. PubMed ID: 32008800
[TBL] [Abstract][Full Text] [Related]
9. Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort.
Kander EM; Raza S; Zhou Z; Gao J; Zakarija A; McMahon BJ; Stein BL
Int J Hematol; 2015 Nov; 102(5):587-93. PubMed ID: 26440973
[TBL] [Abstract][Full Text] [Related]
10. How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms.
Koschmieder S
Hamostaseologie; 2020 Feb; 40(1):47-53. PubMed ID: 32050290
[TBL] [Abstract][Full Text] [Related]
11. Myeloproliferative neoplasms and recurrent thrombotic events in patients undergoing liver transplantation for Budd-Chiari syndrome: a single-center experience.
Oldakowska-Jedynak U; Ziarkiewicz M; Ziarkiewicz-Wróblewska B; Dwilewicz-Trojaczek J; Górnicka B; Nyckowski P; Paluszkiewicz R; Wróblewski T; Zieniewicz K; Patkowski W; Pączek L; Jedrzejczak WW; Krawczyk M
Ann Transplant; 2014 Nov; 19():591-7. PubMed ID: 25394736
[TBL] [Abstract][Full Text] [Related]
12. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders.
Kessler CM
Semin Hematol; 2004 Apr; 41(2 Suppl 3):10-4. PubMed ID: 15190517
[TBL] [Abstract][Full Text] [Related]
13. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms.
Potthoff A; Attia D; Pischke S; Mederacke I; Beutel G; Rifai K; Deterding K; Heiringhoff K; Klempnauer J; Strassburg CP; Manns MP; Bahr MJ
Liver Int; 2015 Aug; 35(8):2042-9. PubMed ID: 25736096
[TBL] [Abstract][Full Text] [Related]
15. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome.
Valla D; Casadevall N; Lacombe C; Varet B; Goldwasser E; Franco D; Maillard JN; Pariente EA; Leporrier M; Rueff B
Ann Intern Med; 1985 Sep; 103(3):329-34. PubMed ID: 4026081
[TBL] [Abstract][Full Text] [Related]
16. Intravascular clotting activation and bleeding in patients with hematologic malignancies.
Tallman MS; Kwaan HC
Rev Clin Exp Hematol; 2004 Jun; 8(1):E1. PubMed ID: 16029967
[TBL] [Abstract][Full Text] [Related]
17. [Budd-Chiari syndrome associated with chronic myeloproliferative syndromes: analysis of 6 cases].
Cobo F; Cervantes F; García-Pagán JC; Bosch J; Rozman C; Montserrat E
Med Clin (Barc); 1996 Nov; 107(17):660-3. PubMed ID: 9064408
[TBL] [Abstract][Full Text] [Related]
18. Bleeding and thrombosis in myeloproliferative disorders.
Landolfi R
Curr Opin Hematol; 1998 Sep; 5(5):327-31. PubMed ID: 9776211
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.
Arachchillage DR; Laffan M
Semin Thromb Hemost; 2019 Sep; 45(6):604-611. PubMed ID: 31382304
[TBL] [Abstract][Full Text] [Related]
20. Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders.
Melear JM; Goldstein RM; Levy MF; Molmenti EP; Cooper B; Netto GJ; Klintmalm GB; Stone MJ
Transplantation; 2002 Oct; 74(8):1090-5. PubMed ID: 12438952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
